Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
67K
-
Shares change
-
+53.8K
-
Total reported value, excl. options
-
$1.17M
-
Value change
-
+$944K
-
Number of buys
-
1
-
Number of sells
-
-1
-
Price
-
$17.54
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q4 2023
2 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q4 2023.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67K shares
.
Largest 10 shareholders include BlackRock Inc. (3.18M shares), VANGUARD GROUP INC (2.97M shares), Rubric Capital Management LP (2.91M shares), Fairmount Funds Management LLC (2.88M shares), BAKER BROS. ADVISORS LP (2.81M shares), MORGAN STANLEY (1.6M shares), Pictet Asset Management Holding SA (1.57M shares), STATE STREET CORP (1.55M shares), GOLDMAN SACHS GROUP INC (909K shares), and Granahan Investment Management, LLC (722K shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.